Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

被引:13
|
作者
Milic, Jovana [1 ,2 ]
Menozzi, Valentina [3 ]
Schepis, Filippo [4 ]
Malagoli, Andrea [1 ]
Besutti, Giulia [2 ]
Franconi, Iacopo [1 ]
Raimondi, Alessandro [1 ]
Carli, Federica [1 ]
Mussini, Cristina [1 ]
Sebastiani, Giada [5 ]
Guaraldi, Giovanni [1 ]
机构
[1] Univ Modena & Reggio Emilia, Modena HIV Metab Clin, Modena, Italy
[2] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Modena & Reggio Emilia, Dept Gastroenterol, Modena, Italy
[5] McGill Univ, Dept Med, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
frailty; HIV; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; METABOLIC SYNDROME; STEATOHEPATITIS; MANAGEMENT; DIAGNOSIS; OBESITY; NAFLD;
D O I
10.1097/QAD.0000000000002650
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019. Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP >= 248 dB/m), while significant liver fibrosis or cirrhosis (stage >= F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4(+) cell count 700 cells/mu l, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4). Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH. Copyright (C) 2020 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1915 / 1921
页数:7
相关论文
共 50 条
  • [21] Non-invasive predictors of advanced liver fibrosis in patients with nonalcoholic fatty liver disease
    Bruining, DH
    Arodak, B
    Silverman, AL
    Gordon, SC
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S110 - S111
  • [22] Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis
    Galvin, Zita
    Rajakumar, Ramraj
    Chen, Emily
    Adeyi, Oyedele
    Selzner, Markus
    Grant, David
    Sapisochin, Gonzalo
    Greig, Paul
    Cattral, Mark
    McGilvray, Ian
    Ghanekar, Anand
    Selzner, Nazia
    Lilly, Les
    Patel, Keyur
    Bhat, Mamatha
    LIVER TRANSPLANTATION, 2019, 25 (01) : 56 - 67
  • [23] Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis
    Choudhary, Narendra S.
    Saigal, Sanjiv
    Saraf, Neeraj
    Soin, Arvinder S.
    LIVER TRANSPLANTATION, 2019, 25 (06) : 967 - 968
  • [24] Molecular mechanisms of steatosis in nonalcoholic fatty liver disease
    Pettinelli, P.
    Obregon, A. M.
    Videla, L. A.
    NUTRICION HOSPITALARIA, 2011, 26 (03) : 441 - 450
  • [25] Nonalcoholic fatty liver disease: From steatosis to cirrhosis
    Farrell, GC
    Larter, CZ
    HEPATOLOGY, 2006, 43 (02) : S99 - S112
  • [26] Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
    Lefere, Sander
    Dupont, Ellen
    De Guchtenaere, Ann
    Van Biervliet, Stephanie
    Vande Velde, Saskia
    Verhelst, Xavier
    Devisscher, Lindsey
    Van Vlierberghe, Hans
    Geerts, Anja
    De Bruyne, Ruth
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (10) : 2317 - +
  • [27] Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis
    Tilg, Herbert
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (17) : 1893 - 1895
  • [28] Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease
    Yao, Mingjie
    Lu, Fengmin
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (10) : 2697 - 2698
  • [29] GALLSTONE DISEASE IS NOT ASSOCIATED WITH LIVER FIBROSIS AND NONALCOHOLIC STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE
    Yilmaz, Y.
    Ayyildiz, T.
    Akin, H.
    Colak, Y.
    Ozturk, O.
    Senates, E.
    Tuncer, I.
    Dolar, E.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S553 - S554
  • [30] In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis
    Africa, Jonathan A.
    Behling, Cynthia A.
    Brunt, Elizabeth M.
    Zhang, Nan
    Luo, Yunjun
    Wells, Alan
    Hou, Jiayi
    Belt, Patricia H.
    Kohil, Rohit
    Lavine, Joel E.
    Molleston, Jean P.
    Newton, Kimberly P.
    Whitington, Peter F.
    Schwimmer, Jeffrey B.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 16 (03) : 438 - +